Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations

Blood

Volumn 91, Issue 11, 1998, Pages 4188-4196

  Ortel, Thomas L ^a   Moore, Karen D ^b   Quinn Allen, Mary Ann ^b   Okamura, Takashi ^b   Sinclair, Allen J ^b   Lazarchick, John ^b   Govindan, Ramaswamy ^b   Carmagnol, Françoise ^b   Kane, William H ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; BINDING SITE; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0032101511     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4188     Document Type: Article

References (34)

1. Ortel TL, Keller FG, Kane WH: Factor V, in High KA, Roberts HR (eds): Molecular Biology of Thrombosis and Hemostasis. New York, NY, Dekker, 1995, p 119
2. Kane WH, Davie EW: Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71:539, 1988
3. Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJ: Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77:405, 1986
4. Coots MC, Muhleman AF, Glueck HI: Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 4:193, 1978
5. Smid WM, de Wolf JTM, Nijland JH, Bom VJJ, Van der Meer J: Severe bleeding caused by an inhibitor to coagulation factor V: A case report. Blood Coagul Fibrinol 5:133, 1994
6. Suehisa E, Toku M, Akita N, Fushimi R, Takano T, Tada H, Iwatani Y, Amino N: Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid. Thromb Res 77:63, 1995
7. Fratantoni JC, Hilgartner M, Nachman RL: Nature of the defect in congenital factor V deficiency: Study in a patient with an acquired circulating anticoagulant. Blood 39:751, 1972
8. Mazzucconi MG, Solinas S, Chistolini A, Motta M, Mariani G: Inhibitor to factor V in severe factor V congenital deficiency. A case report. Nouv Rev Fr Hematol 27:303, 1985
9. Zehnder JL, Leung LLK: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76:2011, 1990
10. Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K: Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 97:84, 1992
11. Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Macik BG: Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol 45:128, 1994
12. Cmolik BL, Spero JA, Magovern GJ, Clark RE, Reid C: Redo cardiac surgery: Late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 105:222, 1993
13. Alving BM, Weinstein MJ, Finlayson JS, Menitove JE, Fratantoni JC: Fibrin sealant: Summary of a conference on characteristics and clinical uses. Transfusion 35:783, 1995
14. Banninger H, Hardegger T, Tobler A, Barth A, Schupbach P, Reinhart W, Lammle B, Furlan M: Fibrin glue in surgery: Frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 85:528, 1993
15. Carroll JF, Moskowitz KA, Edwards NM, Hickey TJ, Rose EA, Budzynski AZ: Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 76:925, 1996
16. Ortel TL, Neal MC, Thames EH, Moore K, Klemp K, Kane WH, Lee ML, Navalta L, Lawson JH: Prospective evaluation of anti-bovine thrombin antibody induction following surgical exposure to bovine thrombin. Thromb Haemost 77:237a, 1997 (abstr, suppl)
17. Ortel TL, Quinn-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH: Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 269:15898, 1994
18. Ortel TL, Quinn-Allen MA, Charles LA, Devore-Carter D, Kane WH: Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest 90:2340, 1992
19. Kane WH, Devore-Carter D, Ortel TL: Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 29:6762, 1990
20. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869, 1975
21. Brandt JT, Britton A, Kraut E: A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 110:224, 1986
22. McGlasson DL, Mercier RJ, Potempa LF, Patterson WR: Platelet-neutralization procedure: Atypical results seen with factor V deficiency with and without inhibitor. Clin Lab Sci 3:119, 1990
23. Ortel TL, Devore-Carter D, Quinn-Allen MA, Kane WH: Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 267:4189, 1992
24. Ortel TL, Quinn-Allen MA, Kane WH: Purification and characterization of the second C-type domain of human factor V expressed in baculovirus. Blood 84:1533a, 1994 (abstr, suppl 1 )
25. Muntean W, Zenz W, Finding K, Zobel G, Beitzke A: Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 83:84, 1994
26. Annamalai AE, Rao AK, Chiu HC, Wang D, Dutta Roy AK, Walsh PN, Colman RW: Epitope mapping of functional domains of human factor Va with human and murine monoclonal antibodies. Evidence for the interaction of heavy chain with factor Xa and calcium. Blood 70:139, 1987
27. Chiu HC, Rao AK, Beckett C, Colman RW: Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 65:810, 1985
28. Cripe LD, Moore KD, Kane WH: Structure of the gene for human coagulation factor V. Biochemistry 31:3777, 1992
29. Kalafatis M, Rand MD, Mann KG: Factor Va-membrane interaction is mediated by two regions located on the light chain of the cofactor. Biochemistry 33:486, 1994
30. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS: Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 75:1999, 1990
31. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 83:1978, 1989
32. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 69:240, 1993
33. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86:1811, 1995
34. Ortel TL, Moore KD: Factor VIII inhibitors that bind to the amino-terminal region of the C2 domain neutralize procoagulant activity and block binding to phosphatidylserine. Blood 88:322a, 1996 (abstr, suppl 1 )